ClinicalTrials.gov
public full text
Public Domain
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder#892839
- Predicting Inflammatory Skin Disease Response to IL-23 Blockade#825656
- Investigating adverse intergenerational effects of prenatal maternal psychological distress through infant gene expression profiles#345353
- Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)#883468
- VA Aripiprazole vs Esketamine for Treatment Resistant Depression#915960
Record · ID 1198153
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive